Mary Simpson, NP
Family · Germantown, TNNPI 1023181864
Payments from drug & device makers
Across 462 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- AbbVie$1K
- Pfizer$967
- Lilly USA, LLC$390
- Amgen$301
- plus $2K from 31 others
What the payments were for
- Food & beverage$8,028100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 84 | $1,562 |
| AstraZeneca | 62 | $1,200 |
| AbbVie | 76 | $1,168 |
| Pfizer | 63 | $967 |
| Lilly USA, LLC | 24 | $390 |
| Amgen | 18 | $301 |
| Bayer | 17 | $259 |
| Boehringer Ingelheim | 14 | $248 |
| GSK | 12 | $193 |
| Abbott | 9 | $192 |
| Baxter Healthcare | 5 | $156 |
| Phathom Pharmaceuticals, Inc. | 9 | $141 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $137 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $114 |
| Sanofi-aventis U.S. LLC | 7 | $101 |
| Astellas Pharma US Inc | 5 | $88 |
| Exact Sciences | 6 | $82 |
| Axsome Therapeutics, Inc. | 3 | $70 |
| Ardelyx, Inc. | 4 | $67 |
| Daiichi Sankyo Inc. | 3 | $63 |
| Supernus Pharmaceuticals, Inc. | 3 | $60 |
| Shield Therapeutics Inc | 3 | $55 |
| Antares Pharma, Inc. | 2 | $51 |
| Merck | 3 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Nestle Healthcare Nutrition Inc. | 2 | $36 |
| Aimmune Therapeutics, Inc. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Averitas Pharma Inc. | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Halozyme Inc | 1 | $23 |
| Corium, LLC | 1 | $22 |
| Genentech USA, Inc. | 1 | $19 |
| Millicent US Inc | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
How this compares
$8,028 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 237 | $274,764 |
| OzempicSemaglutide | 166 | $227,940 |
| EliquisApixaban | 103 | $94,911 |
| JardianceEmpagliflozin | 63 | $70,563 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $45,040 |
| LinzessLinaclotide | 26 | $31,928 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $28,694 |
| MyrbetriqMirabegron | 22 | $23,028 |
| RybelsusSemaglutide | 13 | $21,079 |
| JanuviaSitagliptin Phosphate | 13 | $20,677 |
| FarxigaDapagliflozin Propanediol | 21 | $20,181 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $10,263 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 330 | $5,554 |
| Clindamycin Phosphate | 15 | $4,694 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $3,878 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $390 | $274,764237 claims |
| Novo NordiskOzempic, Rybelsus | $1,562 | $249,020179 claims |
| PfizerEliquis, Premarin | $967 | $97,432115 claims |
| Boehringer IngelheimJardiance | $248 | $70,56363 claims |
| GSKTrelegy Ellipta | $193 | $45,04041 claims |
| AbbVieLinzess, Synthroid | $1,168 | $35,59175 claims |
| Astellas Pharma US IncMyrbetriq | $88 | $23,02822 claims |
| MerckJanuvia | $44 | $20,67713 claims |
| AstraZenecaFarxiga | $1,200 | $20,18121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Germantown
- Chantil JeffreysGermantown$195K
- Jennifer McKeeGermantown$81K
- Laura BargerGermantown$25K
- Melissa BarnesGermantown$19K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.